Psychiatr. pro Praxi, 2004; 4: 201-205

Dlouhodobé podávání kognitiv u Alzheimerovy nemoci

MUDr. Vanda Franková
Psychiatrická léčebna Dobřany

Keywords: Alzheimer disease, cholinesterase inhibitors, memantine, rules of administration.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Franková V. Dlouhodobé podávání kognitiv u Alzheimerovy nemoci. Psychiatr. praxi. 2004;9(4):201-205.

Již v roce 1997 se na našem trhu objevil 1. zástupce skupiny inhibitorů cholinesteráz, léků, které jsou považované za standard v léčbě Alzheimerovy nemoci. Přesto je počet léčených stále ještě nedostačující ve srovnání s ostatními vyspělými státy. Článek shrnuje základní pravidla podávání inhibitorů cholinesteráz a memantinu na základě zpracování literárních údajů a doporučení a s ohledem na zkušenosti autorky.

Long-term use of cognitive drugs in Alzheimer disease

The first representative from a group of cholinesterase inhibitors, which are considered standard therapy of Alzheimer disease, came on our market already in 1997. But still, there are insufficient numbers of treated patients in comparison with other advanced countries. Article summarises basic rules of cholinesterase inhibitors administration based on a review of the literature and recommendations and with regards to the experiences of author.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bullock R. New drugs for Alzheimer´s disease and other dementias. British journal of psychiatry 2002; 180: 135-139. Go to original source... Go to PubMed...
    2. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartarate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer´s disease. Int J Geriatr Psychopharmacology 1998; 1: 55-65.
    3. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003; 11 (2): 131-145. Go to original source...
    4. Delagarza VW. Pharmacologic treatment of Alzheimer´s disease: An update. Am Fam Physician 2003; 68: 1365-1372. Go to PubMed...
    5. Doody RS, Dunn JK, Clark CM, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer´s disease. Dement Geriatr Cogn Disord 2001; 12 (4): 295-300. Go to original source... Go to PubMed...
    6. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality standards subcomittee of the American academy of neurology. Neurology 2001; 56: 1154-1166. Go to original source... Go to PubMed...
    7. Doody RS, Houston TX, Kershaw P. The cognitive benefits of galantamine are sustained for at least 24 months: results of a long-term extension trial in Alzheimer´s disease. Neurology, Apr. 2001; 56 (Suppl. 3): A456.
    8. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Donepezil Study Group: Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch. Neurol. 2001; 58 (3): 427-433. Go to original source... Go to PubMed...
    9. Doody RS. Current treatments for Alzheimer´s disease: Cholinesterase inhibitors. J Clin Psychiatry 2003; 64 (suppl 9): 11-17.
    10. Emre M. Switching cholinesterase inhibitors in patients with Alzheimer´s disease. IJCP 2002; 127 (Suppl): 64-72.
    11. Feldman H, Gauthier S, Hecker J, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in moderate to severe Alzheimer´s disease. Neurology 2001; 57: 613-620. Go to original source... Go to PubMed...
    12. Feldman H, Gauthier S, Hecker J, et al. Donepezil MSAD Study Investigators Group: Efficacy of donepezil to maintenance of activities of daily living in patients with moderate to severe Alzheimer´s disease and the effect on caregiver burden. J. Am. Geriatr. Soc. 2003; 51 (6): 737-744. Go to original source... Go to PubMed...
    13. Folstein MF, Folstein SE, McHugh PR. Mimi-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12: 189-198. Go to original source... Go to PubMed...
    14. Gauthier S. Advances in the pharmacotherapy of Alzheimer´s disease. CMAJ 2002; 166 (5): 616-623. Go to PubMed...
    15. Jirák R. Organické duševní poruchy. In:Höschl C, Libiger J, Švestka J, eds. Psychiatrie. Tigis 2002; 455-480.
    16. Jones RW, Passmore P, Wetterberg P, Soininen H, Bullock R, Murthy A, et al. First head-to-head study comparing the tolerability and efficacy of donepezil and galantamine in Alzheimer´s disease. 7th International Geneva/Springfield Symposium on Advances in Alzheimer´s therapy (AAT); 2002 Apr 3-6; Geneva, Switzerland.
    17. Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR. Efficacy and safety of cholinesterase inhibitors in Alzheimer´s disease: a meta-analysis. CMAJ 2003; 169 (6): 557-564. Go to PubMed...
    18. Mohs RC, Doody RS, Morris JC, et al. For the 312 Study group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-488. Go to original source... Go to PubMed...
    19. NICE issues guidance on drugs for Alzheimer´s disease. National institute for clinical excellence (2001). 4/2004 na: www.nice.org.uk/Docref.asp?d=14412.
    20. Raskind MA, Peskind ER, Wessel T, Yuan W, and the Galantamine USA-1 Study Group: Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-2268. Go to original source... Go to PubMed...
    21. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaaju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004; 61(2): 252-256. Go to original source... Go to PubMed...
    22. Raskind MA, Truyen L, Lilienfeld S. Galantamine is safe and effective during long-term therapy in patients with Alzheimer´s disease. Poster presented at the 127th Annual meeting of the American neurological association, New York, October 13-16, 2002.
    23. Reisberg B, Ferris HM, deLeon J, Crook T. The global deterioration scale for assessment primary degenerative dementia. Am J Psych 1982; 139: 1136-1139. Go to original source... Go to PubMed...
    24. Reisberg B, Windschief U, Ferris SH, et al: Memantine in moderately severe to severe Alzheimer´s disease(AD): Results of a placebo-controlled 6-month trial. Neurobiol. of Aging, 2000; 21 (suppl. 1): S275. Go to original source...
    25. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine Study Group: Memantine in moderate-to-severe Alzheimer´s disease. N. Engl. J. Med. 2003 Apr 3; 348 (14): 1333-1341. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.